<p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）在週六發佈的一份報告中被華爾街 Zen 的股票研究人員從 “強力買入” 評級下調至 “買入” 評級。</p>
<p>獲取 <strong>Globus Medical</strong> 警報：</p>
<p>其他一些研究分析師也對 GMED 發表了評論。加拿大皇家銀行在週五的一份研究報告中將 Globus Medical 的目標價格從 115.00 美元上調至 120.00 美元，並給予該公司 “跑贏大盤” 的評級。Weiss Ratings 在 4 月 15 日（星期三）的一份研究報告中重申了對 Globus Medical 股票的 “持有（c+）” 評級。Needham &amp; Company LLC 在週五的一份研究報告中將 Globus Medical 的目標價格從 114.00 美元上調至 117.00 美元，並給予該公司 “買入” 評級。Truist Financial 在 2 月 25 日（星期三）的一份研究報告中設定了 Globus Medical 的目標價格為 115.00 美元。最後，Zacks Research 在 3 月 3 日（星期二）的一份研究報告中將 Globus Medical 的評級從 “持有” 上調至 “強力買入”。兩位投資分析師給予該股票 “強力買入” 評級，九位分析師給予 “買入” 評級，五位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為 106.36 美元。</p>
<p><strong>獲取我們最新的 GMED 研究報告</strong></p>
<h2>Globus Medical 股票表現</h2>
<p>GMED 的股票在週五開盤價為 77.81 美元。該公司的市值為 105.2 億美元，市盈率為 18.10，PEG 比率為 1.99，貝塔值為 1.00。該公司的 50 日移動平均價格為 89.86 美元，200 日移動平均價格為 86.65 美元。Globus Medical 的 52 周低點為 51.79 美元，52 周高點為 101.40 美元。</p>
<p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）最近在 5 月 7 日（星期四）公佈了季度財報。這家醫療設備公司報告本季度每股收益為 1.12 美元，超出分析師共識預期的 0.92 美元，超出幅度為 0.20 美元。該公司的季度收入為 7.5985 億美元，而分析師預期為 7.4035 億美元。Globus Medical 的股本回報率為 13.69%，淨利潤率為 18.92%。該公司的季度收入同比增長 27.0%。去年同期，該公司每股收益為 0.68 美元。Globus Medical 已將其 2026 財年的指導目標設定為每股收益 4.700-4.800 美元。整體來看，研究分析師預測 Globus Medical 在當前年度將發佈每股收益 4.46 美元。</p>
<h2>內部活動</h2>
<p>在其他新聞中，執行副總裁 Kelly Huller 在 2 月 25 日（星期三）出售了該公司 20,000 股股票。該股票的平均售價為 94.50 美元，總價值為 1,890,000.00 美元。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。18.38% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>幾家對沖基金和其他機構投資者最近對 GMED 的持倉進行了調整。Invesco Ltd.在第四季度將其在 Globus Medical 的持倉增加了 1,235.2%。Invesco Ltd.目前擁有 3,886,405 股該醫療設備公司的股票，價值 339,322,000 美元，此前在上個季度購買了額外的 3,595,339 股。蒙特利爾銀行在第四季度將其在 Globus Medical 的持倉增加了 15,317.1%。蒙特利爾銀行目前擁有 3,373,260 股該醫療設備公司的股票，價值 294,519,000 美元，此前在上個季度購買了額外的 3,351,380 股。Alliancebernstein L.P.在第三季度將其在 Globus Medical 的持倉增加了 1,303.9%。Alliancebernstein L.P.目前擁有 2,055,183 股該醫療設備公司的股票，價值 117,700,000 美元，此前在上個季度購買了額外的 1,908,795 股。Fuller &amp; Thaler Asset Management Inc.在第四季度購買了 Globus Medical 的新頭寸，價值 90,411,000 美元。最後，挪威銀行在第四季度購買了 Globus Medical 的新頭寸，價值 89,922,000 美元。目前 95.16% 的股票由機構投資者持有。</p>
<h2>Globus Medical 新聞匯總</h2>
<p>以下是本週影響 Globus Medical 的主要新聞：</p>
<ul>
<li>積極情緒：Globus Medical 在第一季度的業績和收入均超出預期，報告每股收益 1.12 美元，預期為 0.92 美元，銷售額為 7.599 億美元，預期為 7.404 億美元；收入同比增長 27%，利潤率改善。文章標題</li>
<li>積極情緒：該公司還將 2026 財年的每股收益指導上調至 4.70-4.80 美元，高於共識，顯示管理層對持續增長的信心。文章標題</li>
<li>積極情緒：加拿大皇家銀行將 GMED 的目標價格從 115 美元上調至 120 美元，並維持 “跑贏大盤” 評級，而 Needham 將目標價格從 114 美元上調至 117 美元，並重申 “買入” 評級，反映出分析師的樂觀情緒。文章標題</li>
<li>中性情緒：投資者也在消化該公司的第一季度財報電話會議記錄及相關的財報後報道，主要強調強勁的業績，而不是增加新的催化劑。文章標題</li>
<li>消極情緒：儘管業績超出預期且指導上調，但股票仍然下跌，交易者似乎在獲利了結，並關注在報告發布前已經提升的預期。文章標題</li>
</ul>
<h2>關於 Globus Medical</h2>
<p>（獲取免費報告）</p>
<p>Globus Medical, Inc（紐約證券交易所代碼：GMED）是一家領先的醫療設備公司，專注於脊柱和骨科應用的肌肉骨骼解決方案。該公司成立於 2003 年，由 David C. Paul 創立，總部位於賓夕法尼亞州 Audubon，開發、製造和銷售旨在治療脊柱疾病和促進骨癒合的植入設備和外科器械。其產品組合涵蓋了用於微創和開放手術的解決方案，包括椎間融合設備、椎弓根螺釘系統和用於增強融合效果的生物製劑。</p>
<p>除了其核心脊柱業務外，Globus Medical 還擴展到了機器人和導航系統，以支持手術室的精確性和效率。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們認為比 Globus Medical 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Globus Medical 嗎？</h2>
<p>在考慮 Globus Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Globus Medical 並不在名單上。</p>
<p>雖然 Globus Medical 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Globus醫療

<p>華爾街禪將 Globus Medical（NYSE:GMED）的評級從 “強力買入” 下調至 “買入”。其他分析師的看法不一，加拿大皇家銀行將其目標價上調至 120 美元，Needham 則上調至 117 美元，均維持積極評級。該股開盤價為 77.81 美元，市值為 105.2 億美元。Globus Medical 報告了強勁的第一季度業績，EPS 為 1.12 美元，營收為 7.5985 億美元，較去年同期增長 27%。公司還將 2026 財年的 EPS 指引上調至 4.70-4.80 美元，顯示出增長信心</p>

<p>Globus Medical (NYSE:GMED - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report issued on Saturday.</p>
<div class="lb-trans"><p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）在週六發佈的一份報告中被華爾街 Zen 的股票研究人員從 “強力買入” 評級下調至 “買入” 評級。</p>
</div><p>Get <strong>Globus Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Globus Medical</strong> 警報：</p>
</div><p>A number of other research analysts have also commented on GMED. Royal Bank Of Canada increased their price objective on Globus Medical from $115.00 to $120.00 and gave the company an &#34;outperform&#34; rating in a research report on Friday. Weiss Ratings reiterated a &#34;hold (c+)&#34; rating on shares of Globus Medical in a research report on Wednesday, April 15th. Needham &amp; Company LLC increased their price objective on Globus Medical from $114.00 to $117.00 and gave the company a &#34;buy&#34; rating in a research report on Friday. Truist Financial set a $115.00 price objective on Globus Medical in a research report on Wednesday, February 25th. Finally, Zacks Research upgraded Globus Medical from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $106.36.</p>
<div class="lb-trans"><p>其他一些研究分析師也對 GMED 發表了評論。加拿大皇家銀行在週五的一份研究報告中將 Globus Medical 的目標價格從 115.00 美元上調至 120.00 美元，並給予該公司 “跑贏大盤” 的評級。Weiss Ratings 在 4 月 15 日（星期三）的一份研究報告中重申了對 Globus Medical 股票的 “持有（c+）” 評級。Needham &amp; Company LLC 在週五的一份研究報告中將 Globus Medical 的目標價格從 114.00 美元上調至 117.00 美元，並給予該公司 “買入” 評級。Truist Financial 在 2 月 25 日（星期三）的一份研究報告中設定了 Globus Medical 的目標價格為 115.00 美元。最後，Zacks Research 在 3 月 3 日（星期二）的一份研究報告中將 Globus Medical 的評級從 “持有” 上調至 “強力買入”。兩位投資分析師給予該股票 “強力買入” 評級，九位分析師給予 “買入” 評級，五位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為 106.36 美元。</p>
</div><p><strong>Get Our Latest Research Report on GMED</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 GMED 研究報告</strong></p>
</div><h2>Globus Medical Stock Performance</h2>
<div class="lb-trans"><h2>Globus Medical 股票表現</h2>
</div><p>Shares of GMED opened at $77.81 on Friday. The firm has a market capitalization of $10.52 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 1.99 and a beta of 1.00. The business's fifty day moving average price is $89.86 and its two-hundred day moving average price is $86.65. Globus Medical has a 52 week low of $51.79 and a 52 week high of $101.40.</p>
<div class="lb-trans"><p>GMED 的股票在週五開盤價為 77.81 美元。該公司的市值為 105.2 億美元，市盈率為 18.10，PEG 比率為 1.99，貝塔值為 1.00。該公司的 50 日移動平均價格為 89.86 美元，200 日移動平均價格為 86.65 美元。Globus Medical 的 52 周低點為 51.79 美元，52 周高點為 101.40 美元。</p>
</div><p>Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 13.69% and a net margin of 18.92%.The business's quarterly revenue was up 27.0% compared to the same quarter last year. During the same period last year, the company earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts forecast that Globus Medical will post 4.46 EPS for the current year.</p>
<div class="lb-trans"><p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）最近在 5 月 7 日（星期四）公佈了季度財報。這家醫療設備公司報告本季度每股收益為 1.12 美元，超出分析師共識預期的 0.92 美元，超出幅度為 0.20 美元。該公司的季度收入為 7.5985 億美元，而分析師預期為 7.4035 億美元。Globus Medical 的股本回報率為 13.69%，淨利潤率為 18.92%。該公司的季度收入同比增長 27.0%。去年同期，該公司每股收益為 0.68 美元。Globus Medical 已將其 2026 財年的指導目標設定為每股收益 4.700-4.800 美元。整體來看，研究分析師預測 Globus Medical 在當前年度將發佈每股收益 4.46 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other news, EVP Kelly Huller sold 20,000 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 18.38% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁 Kelly Huller 在 2 月 25 日（星期三）出售了該公司 20,000 股股票。該股票的平均售價為 94.50 美元，總價值為 1,890,000.00 美元。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。18.38% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in GMED. Invesco Ltd. boosted its position in shares of Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company's stock worth $339,322,000 after purchasing an additional 3,595,339 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Globus Medical by 15,317.1% in the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company's stock worth $294,519,000 after purchasing an additional 3,351,380 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company's stock worth $117,700,000 after purchasing an additional 1,908,795 shares during the last quarter. Fuller &amp; Thaler Asset Management Inc. bought a new position in shares of Globus Medical in the 4th quarter worth $90,411,000. Finally, Norges Bank bought a new position in shares of Globus Medical in the 4th quarter worth $89,922,000. 95.16% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對 GMED 的持倉進行了調整。Invesco Ltd.在第四季度將其在 Globus Medical 的持倉增加了 1,235.2%。Invesco Ltd.目前擁有 3,886,405 股該醫療設備公司的股票，價值 339,322,000 美元，此前在上個季度購買了額外的 3,595,339 股。蒙特利爾銀行在第四季度將其在 Globus Medical 的持倉增加了 15,317.1%。蒙特利爾銀行目前擁有 3,373,260 股該醫療設備公司的股票，價值 294,519,000 美元，此前在上個季度購買了額外的 3,351,380 股。Alliancebernstein L.P.在第三季度將其在 Globus Medical 的持倉增加了 1,303.9%。Alliancebernstein L.P.目前擁有 2,055,183 股該醫療設備公司的股票，價值 117,700,000 美元，此前在上個季度購買了額外的 1,908,795 股。Fuller &amp; Thaler Asset Management Inc.在第四季度購買了 Globus Medical 的新頭寸，價值 90,411,000 美元。最後，挪威銀行在第四季度購買了 Globus Medical 的新頭寸，價值 89,922,000 美元。目前 95.16% 的股票由機構投資者持有。</p>
</div><h2>Globus Medical News Roundup</h2>
<div class="lb-trans"><h2>Globus Medical 新聞匯總</h2>
</div><p>Here are the key news stories impacting Globus Medical this week:</p>
<div class="lb-trans"><p>以下是本週影響 Globus Medical 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title</li>
<li>Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title</li>
<li>Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title</li>
<li>Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title</li>
<li>Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Globus Medical 在第一季度的業績和收入均超出預期，報告每股收益 1.12 美元，預期為 0.92 美元，銷售額為 7.599 億美元，預期為 7.404 億美元；收入同比增長 27%，利潤率改善。文章標題</li>
<li>積極情緒：該公司還將 2026 財年的每股收益指導上調至 4.70-4.80 美元，高於共識，顯示管理層對持續增長的信心。文章標題</li>
<li>積極情緒：加拿大皇家銀行將 GMED 的目標價格從 115 美元上調至 120 美元，並維持 “跑贏大盤” 評級，而 Needham 將目標價格從 114 美元上調至 117 美元，並重申 “買入” 評級，反映出分析師的樂觀情緒。文章標題</li>
<li>中性情緒：投資者也在消化該公司的第一季度財報電話會議記錄及相關的財報後報道，主要強調強勁的業績，而不是增加新的催化劑。文章標題</li>
<li>消極情緒：儘管業績超出預期且指導上調，但股票仍然下跌，交易者似乎在獲利了結，並關注在報告發布前已經提升的預期。文章標題</li>
</ul>
</div><h2>About Globus Medical</h2>
<div class="lb-trans"><h2>關於 Globus Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.</p>
<div class="lb-trans"><p>Globus Medical, Inc（紐約證券交易所代碼：GMED）是一家領先的醫療設備公司，專注於脊柱和骨科應用的肌肉骨骼解決方案。該公司成立於 2003 年，由 David C. Paul 創立，總部位於賓夕法尼亞州 Audubon，開發、製造和銷售旨在治療脊柱疾病和促進骨癒合的植入設備和外科器械。其產品組合涵蓋了用於微創和開放手術的解決方案，包括椎間融合設備、椎弓根螺釘系統和用於增強融合效果的生物製劑。</p>
</div><p>In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.</p>
<div class="lb-trans"><p>除了其核心脊柱業務外，Globus Medical 還擴展到了機器人和導航系統，以支持手術室的精確性和效率。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Globus Medical</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Globus Medical 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=GMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Globus Medical 嗎？</h2>
</div><p>Before you consider Globus Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Globus Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Globus Medical 並不在名單上。</p>
</div><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Globus Medical 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Globus Medical (NYSE:GMED) Stock Rating Lowered by Wall Street Zen

Market Beat

Globus Medical（紐約證券交易所代碼：GMED）的股票評級被 Wall Street Zen 下調